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Exists After Transcatheter Aortic Valve Implantation
Objectives This study assesses if there exists a high-risk period for cerebrovascular events (CeV)
after transcatheter aortic valve implantation (TAVI).
Background Even though acute strokes after TAVI have been described, it is uncertain if stroke
rates continue to remain high in the early months after TAVI. Furthermore, the optimal dose and
duration of thromboprophylaxis is unclear.
Methods Patients who underwent TAVI were evaluated at baseline, at discharge, at 1 and 6
months, and yearly. Risk factors for CeV events, procedural details, and antithrombotic therapy were
recorded. Outcomes assessed were CeV events and death. The timing of such events, predictors,
and impact on survival were analyzed.
Results A total of 253 patients were assessed. Median age was 85 years. The median Society of Tho-
racic Surgeons score was 8.1% (interquartile range [IQR]: 5.5% to 12.0%). Risk factors included smoking
(47%), hypertension (70%), dyslipidemia (66%), and diabetes mellitus (25%). Twenty-three percent had
known cerebrovascular disease and 39% had atrial ﬁbrillation. Median follow-up was 455 days (IQR: 160 to
912 days) at which time 23 patients experienced a CeV event. The incidence was highest in the ﬁrst 24 h but
remained high for 2 months. In-hospital mortality rate after a CeV event was 21%. A prior history of CeV dis-
ease was an independent predictor of an event (hazard ratio: 4.23, 95% CI: 1.60 to 11.11, p  0.004).
Conclusions The incidence of CeV events is highest within 24 h of TAVI, but this risk may remain
elevated for up to 2 months. A prior history of cerebrovascular disease is an independent predictor.
This may have implications for patient selection and antithrombotic strategies. (J Am Coll Cardiol























fTranscatheter aortic valve implantation (TAVI) has been
used increasingly to treat symptomatic patients with severe
aortic stenosis, who are deemed to be high-risk patients for
conventional surgery. Although mortality rates have been
declining with increasing operator experience and device
improvements, cerebrovascular event (CeV) complications
continue to occur (1,2). The pathophysiology, timing, types,
nd prognosis of these events after TAVI are unclear. Most
tudies have focused on the immediate CeVs after TAVI,
ut there may be a residual period of high risk after an
nitially successful procedure.
Moreover, addressing CeV after TAVI is important for
everal reasons. Strokes occurring immediately after surgical
ioprosthetic implants have devastating consequences; apart
rom high mortality rates (3), the supposed benefits of TAVI
n improving quality of life in these patients is abolished (4).
he cost-effectiveness of TAVI may also be lost. Most
mportantly, understanding these events may facilitate de-
elopment of risk reduction strategies.
ethods
Patients. All patients with symptomatic severe valvular aortic
tenosis who underwent TAVI between January 2005 and wovember 2009 were assessed. Patients enrolled in the
ARTNER (Placement of Aortic Transcatheter Valves)
rial were excluded from this study. Acceptance for TAVI
equired a consensus among a team of senior cardiac
urgeons and interventional cardiologists that the risk of
onventional surgery was excessive. Informed consent was
btained. Standard transfemoral or transapical TAVI tech-
iques were used (5,6). Before 2008, antiplatelet therapy
as not standardized for TAVI although most transfemoral
rocedure patients received dual antiplatelet agents adopted
rom coronary stenting recommendations. After 2008, un-
ess contraindicated, it was recommended to managing
hysicians that all patients should receive a loading dose of
lopidogrel (300 mg) or aspirin (325 mg) before TAVI and
hen 75 mg (of clopidogrel) and 81 mg (of aspirin) as
aintenance therapy for 6 months (PARTNER trial protocol
nd recommendations from Medtronic CoreValve [Medtronic
V Luxembourg S.a.r.l., Luxembourg] [7]). Most transapical
ases did not receive clopidogrel because of concerns of
leeding. Intraprocedural anticoagulation was achieved using
ntravenous heparin with activated clotting time maintained
bove 250 s. Baseline characteristics, including known risk
actors for strokes were assessed. Prior cerebrovascular disease
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1292ultrasound, carotid endarterectomy, previous strokes, or tran-
sient ischemic attacks (TIA). Intraprocedural events, as well as
post-procedure antiplatelet and antithrombotic therapy were
recorded. In this study, antithrombotic therapies refer to the
use of heparin or vitamin K antagonists (VKA), such as
warfarin. In patients who experienced a CeV, the type of
antiplatelet or antithrombotic agent received before the event
was also documented.
Cerebrovascular events included TIA and clinical strokes
(ischemic or hemorrhagic). A TIA was defined as a brief
episode of neurological dysfunction (lasting 24 h) result-
ing from focal cerebral ischemia and not associated with
evidence of cerebral infarction on imaging (computed to-
mography or magnetic resonance imaging). Clinical strokes
were defined as acute neurological dysfunction that lasted
more than 24 h with evidence of infarction on computed
tomography or magnetic resonance imaging. A neurologist
or internist made the diagnoses in all patients.
In this study, peripheral vascular disease was defined as
the presence of claudication at
rest or exertion, previous ampu-
tations for peripheral artery dis-
ease, angioplasties, bypasses, or
detection of disease on noninva-
sive testing. Hemodynamic in-
stability was defined as hypoten-
sion refractory to inotropic
support alone requiring cardio-
pulmonary resuscitation, intra-
aortic balloon pump insertion, or
extracorporeal membrane oxy-
genation.
Mortality and CeV during the
initial hospitalization were pro-
spectively recorded. This was
similarly done for those who were readmitted to the TAVI
heart center. Post-discharge events were evaluated by clin-
ical review of patients’ charts via telephone calls made to
patients, their families, or their physicians (internist, neu-
rologist, cardiologists) that occurred at 1 and 6 months and
yearly.
Statistical analysis. Categorical variables were expressed as
numbers (percentages) and continuous variables as mean SD
r medians and first or third quartiles when not normally
istributed. Shapiro-Wilks goodness-of-fit test was used to
est normality. Comparisons were made between patients who
eveloped CeV and those who did not using Student t test or
ann-Whitney U test and chi-square or Fisher exact test as
ppropriate. Univariate analyses were performed to identify
redictors of CeV. A stepwise backward multivariable analysis
as then performed to determine independent predictors.
inally, an adjusted Cox proportional hazards regression model





CI  confidence interval
R  hazard ratio
QR  interquartile range
AVI  transcatheter aortic
alve implantation
IA  transient ischemic
ttack(s)
KA  vitamin K
ntagonist(s)onstructed and analyzed. Its effect was quantified using theazard ratio (HR) estimate and its 95% confidence interval
CI). All statistics were performed using SPSS (version 15.0,
PSS Inc., Chicago, Illinois).
esults
A total of 253 patients underwent TAVI from January 2005
to November 2009. The median age was 85 years and 51%
were men (Table 1). Overall surgical risks of these patients
were high with a median logistic EuroSCORE (European
System for Cardiac Operative Risk Evaluation) and Society
of Thoracic Surgeons score of 28% (interquartile range
[IQR]: 16% to 40%) and 8.1% (IQR: 5.5% to 12.0%),
respectively. Significant proportions of patients were smok-
ers (47%) and had risk factors of hypertension (70%),
dyslipidemia (66%), and diabetes mellitus (25%). Twenty-
three percent of patients had a history of prior cerebrovas-
cular disease and more than one-third had atrial fibrillation.
The median follow-up for this study was 455 days (IQR:
160 to 912 days). During this time, 23 patients experienced
CeV. Patients with CeV had a higher incidence of baseline
cerebrovascular disease (48% vs. 20%, p  0.007). There
was no significant difference in the prevalence of atheroscle-
rotic risk factors or known embolic risk factors, such as
concomitant atrial fibrillation or reduced ejection fraction.
Other known risk factors of stroke after surgical aortic valve
replacement, such as renal function, hemoglobin, and coex-
istent peripheral artery disease, were not significantly dif-
ferent between those who had CeV versus those that did
not. A higher percentage of patients undergoing the trans-
femoral procedure versus the transapical procedure had
CeV, but this was not statistically significant (10.7% vs.
5.9%, p  0.24). With regard to antiplatelet therapy,
two-thirds of the patients (n  168) were on clopidogrel
before TAVI. One hundred thirty-four patients received a
loading dose 6 h before the procedure, whereas 34 were
already on a steady dose of 75 mg daily for 1 week.
Patients undergoing the transapical procedure did not re-
ceive clopidogrel before TAVI and 8 had their maintenance
dose of clopidogrel discontinued for 5 days before TAVI.
Two hundred thirty-four (93%) patients were on aspirin
before TAVI. Overall use of aspirin (89%), clopidogrel
(59%), and antithrombotic therapy (heparin or warfarin)
(33%) were high at discharge. Among patients who devel-
oped CeV, 91% were on aspirin, 61% were on clopidogrel,
and 35% were receiving antithrombotic therapy at the time
of the event.
Timing and types of events. Most CeV (n  20, 87%)
occurred within 2 months of TAVI, of which, one-half (n
11) occurred within the first 24 h of the procedure (Fig. 1).
These early events were mostly ischemic strokes (n  9), of
which 2 occurred after documented episodes of prolonged
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after the procedure (n  6, 2.5%) and became less frequent in
the second (n  2, 0.8%) month. Late CeV were infrequent
n  4) and occurred at days 126, 180, 200, and 600.
The most common location of cerebral infarction was the
middle cerebral artery territory followed by the posterior
circulation (4 patients presented with cerebellar dysfunction,
Table 1. Clinical Characteristics: Only Advanced Age
Univariate Predictors of Stroke
All (N  253
Age, yrs 85 (79–89)
Weight, kg 71.0 16.3





Atrial ﬁbrillation 98 (39)
Smoking 118 (47)
Coronary artery disease 191 (76)
Previous stroke 43 (17)
Previous cerebrovascular disease 58 (23)
Prior carotid imaging 35 (14)
Peripheral vascular disease 83 (33)
Transfemoral 168 (66)
Delivery systems
RF 1 and 2 127 (50)
RF 3/Novaﬂex 36 (14)
CoreValve 18-F 5 (2)
Ascendra 85 (34)
Activated clotting time, s 267.1 85.2
Hemodynamic instability 12 (5)
Redilation 47 (19)
Clopidogrel pre-treatment
Naive with loading dose 134 (53)
Continued stable dose 34 (14)
Discontinued 8 (3)
Naive with no loading 77 (30)
Aspirin pre-treatment
Loading dose 57 (23)
Continued stable dose 177 (70)
No aspirin 19 (7)
Clopidogrel at time of event 148 (59)
Aspirin at time of event 224 (89)
Antithrombotic therapy at time of event 84 (33)
Glomerular ﬁltration rate, ml/kg/min 57.7 24.2
Left ventricular ejection fraction, % 54.8 14.1
Hemoglobin, g/dl 121.9 16.0
Logistic EuroSCORE, % 28 (16–40)
Society of Thoracic Surgeons score, % 8.1 (5.5–12.0)
Values are median (interquartile range), mean SD, or n (%). Novafle
CoreValve is a product of Medtronic CV Luxembourg S.a.r.l. (Luxembo
CeV cerebrovascular event(s); EuroSCORE European System foand 1 presented with cortical blindness from bilateral Toccipital infarcts) (Fig. 2). Fifteen percent of patients had
infarction in multiple territories. Lacunar infarcts and in-
ternal capsule infarcts were less common.
Prognosis and predictors of CeV. Patients who had early,
n-hospital CeV had a trend toward higher mortality rates
ompared with those that did not (21% vs. 8%, p  0.08).
edian follow-up was 455 days (IQR: 160 to 912 days).
Prior History of Cerebrovascular Disease Were
CeV (n  23) No CeV Event (n  230) p Value
87 (83–92) 85 (79–89) 0.05
71.3 15.0 71.4 16.3 0.97
165.7 11.1 166.3 10.2 0.81
11 (48) 118 (51) 0.82
8 (35) 56 (24) 0.31
17 (74) 160 (70) 0.81
16 (70) 150 (65) 0.82
11 (49) 87 (38) 0.38
10 (44) 108 (47) 0.83
17 (74) 174 (76) 0.80
7 (30) 36 (16) 0.08
11 (48) 47 (20) 0.007
7 (30) 28 (12) 0.025
7 (30) 76 (33) 1.00
18 (78) 150 (65) 0.24
0.27
14 (61) 113 (49)
3 (13) 33 (14)
1 (4) 4 (2)
5 (22) 80 (35)
269.3 52.4 266.8 89.5 0.87
2 (9) 10 (4) 0.30
6 (26) 41 (18) 0.43
0.42
13 (56) 121 (53)
5 (22) 29 (13)
0(0) 8 (3)
5 (22) 72 (31)
0.79
6 (26) 51 (22)
16 (70) 161 (70)
1 (4) 18 (7.8)
14 (61) 134 (58) 0.35
21 (91) 203 (88) 1.00
8 (35) 76 (33) 0.83
50.5 22.0 58.5 24.3 1.00
59.6 11.0 54.4 14.3 0.04
124.9 21.5 121.6 15.4 0.49
18 (14–32) 28 (16–41) 0.15
10.6 (5.1–13.8) 7.9 (5.5–11.9) 0.19
scendra are products of Edwards Lifesciences Inc. (Irvine, California).
c Operative Risk Evaluation; RF Retroflex.and a
)
x and A
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1294clearly predict increased mortality over time with the HR of
1.06 (95% CI: 0.46 to 2.46), p  0.89. Known predictors of
eV after surgical bioprosthetic aortic valve replacement,
ncluding age, diabetes mellitus, hypertension, dyslipidemia,
revious cerebrovascular disease, renal function, peripheral
ascular disease, atrial fibrillation, left ventricular ejection
raction, access site chosen, redilation of the aortic valve,
nd the use of antiplatelet and antithrombotic therapy were
ssessed. On multivariate analyses, only a history of cere-
rovascular disease remained an independent predictor of
troke (HR: 4.23, 95% CI: 1.60 to 11.11, p  0.004).
lthough the numbers of patients having prior carotid
ltrasonography was low, among those with carotid stenosis
f 50%, 7 patients (20%) developed CeV on follow-up.
iscussion
This study demonstrates that CeV after TAVI occur most
frequently in the first 24 h, but the incidence remains
elevated through the first 2 months. Periprocedural CeV are
associated with high in-hospital mortality.
Our study results are consistent with the published results
of the PARTNER trial. In cohort A, the combined CeV
was 5.5% at 30 days and 8.3% at 1 year, whereas in cohort
B, it was 6.7% and 10.6%, respectively. This study focuses,
however, on the timing of these events (8,9).
Immediate post-procedural events. No prior studies have
escribed the timing and types of CeV after TAVI. Current
nformation on this issue comes predominantly from expe-
ience after surgical bioprosthetic valve implants. Throm-
oembolic risk is high immediately after surgical valve
mplantation (10). Immediate post-procedural CeV may be
ue to disruption of atheromatous or calcific debris intra-
peratively. Cerebral ischemia can also occur due to peripro-
edural hypotension. The similarly high incidence seen in
Figure 1. Timing of CeV After TAVI
Most events occur in the ﬁrst 24 h. The incidence of events then dimin-
ishes after day 60. CeV  cerebrovascular event(s); TAVI  transcatheter
aortic valve implantation; TIA  transient ischemic attack(s).his TAVI study in the first 24 h may be attributed tombolism of debris during valve implantation as catheters,
ires, and devices traverse the aortic arch, balloon aortic
alvuloplasty (11), valve deployment or redilation, or hypo-
ensive episodes. In addition, thrombi can form on devices/
ires during the procedure. The location of cerebral infarcts
een in this study is typical of embolic infarcts (12), with a
arge proportion localized in the middle cerebral artery
erritory, posterior circulatory system, or involving multiple
oci. Preventive strategies for the immediate periprocedural
eriod include meticulous care with hemodynamic support
nd adequate anticoagulation during the procedure. Newer
evices that deflect or filter emboli are also currently being
nvestigated.
Later events. The incidence of CeV continues to be high
after the first 24 h and persists up to the first 60 days after
TAVI. During this period, the bioprosthesis itself may be a
source of thromboemboli before endothelialization of the
prosthesis completes (13,14). Aggregation of platelet and
fibrin has been known to occur on valve leaflet within a few
hours after implantation. It is uncertain how much more
thrombogenic a transcatheter valve is compared with a
conventional surgical bioprosthesis. First, the impact of
crimping the valve within a stent followed by balloon
dilation on the surface characteristics of these valves is
unknown. Second, a fabric, sealing cuff covering the inflow
portion of the transcatheter heart valve intended to prevent
paravalvular leak may not be completely opposed to the
aortic wall leading to stasis and possible thrombus forma-
tion. The native valve leaflets, which may be fissured or
denuded are left compressed adjacent to the stent frame,
which again has unknown thrombogenic consequences.
Finally, endothelialization of stent struts may not be com-
plete (Fig. 3) (15). To reduce thromboembolic risk, most
atients in this center were on dual antiplatelet agents after
AVI for up to 3 to 6 months. There is, however, little
vidence to support this practice other than fact that this
Figure 2. Location of Infarcts
Most infarcts occur in the middle cerebral artery (MCA) territory followed
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1295approximates the time required for endothelialization over
stainless steel coronary stents (16). It is also unclear if the
se of antithrombotic therapies, such as VKA might reduce
eV. This study was not large enough to detect differences
n CeV rates among patients who used antiplatelet agents or
ntithrombotic therapies.
It may be relevant to consider recommendations for aortic
urgical bioprostheses. The American College of Cardiology/
merican Heart Association guidelines recommend aspirin
lone in patients without additional risk factors, but they
tate that warfarin for 3 months is reasonable (17). How-
ver, the European Society of Cardiology guidelines recom-
end 3 months of VKA (18). These differences have arisen
s some studies suggest that VKA is effective, whereas
thers suggest benefit is limited to high-risk subsets (pa-
Figure 3. Pathological Images Showing Incomplete Endothelialization
(A) Postmortem of a patient who died on day 25 from pulseless ventricular
tachycardia. (B) Postmortem of a patient who died on day 28 after implan-
tation from stroke-related complications. Several stent struts are not endo-
thelialized (black arrow) in this patient. Areas with tissue ingrowth (white
arrow) are also shown for comparison.ients with low left ventricular ejection fraction or atrialbrillation) (19). Other studies have demonstrated no sig-
ificant differences between antiplatelet agents and VKA
20–22). The optimal preventive strategy in the early few
onths thus remains elusive for surgical bioprostheses, and
ven more so after TAVI. It is worthwhile to note that
hereas strokes continue to occur late after 60 days, this
robably reflects the background risks of this population and
s unlikely to be related to the valve/procedure. When
onsidering VKA use, it is important to note that 2 patients
ad a hemorrhagic stroke. In addition, the use of triple
herapy (VKA, aspirin, and thienopyridines) has been asso-
iated with significantly increased bleeding risk (23).
Predictors of stroke. This study identified a prior history of
cerebrovascular disease as a predictor of CeV. These pa-
tients should be made aware of their risk during the consent
process and managed with greater care. Currently, it is
unknown if routine screening for cerebrovascular disease
(e.g., carotid or ascending aortic imaging) would have an
impact on outcomes. However, the high incidence of CeV
in those with carotid stenosis of50% in this study suggests
that this potential predictor should be explored in the
future. It was interesting to note that atrial fibrillation was
not a risk predictor of stroke in this study. In addition,
the use of warfarin in patients with atrial fibrillation was
not significantly different for those without (36% vs. 32%,
p  0.50).
Prognosis. The in-hospital mortality rate among patients
who developed CeV after TAVI was high (21%). In this
study, CeV and their impact on midterm survival were not
statistically significant and are likely due to the small
number of events in this cohort. Larger studies in the future
may be required to assess this further. This reflects a sicker
cohort of patients who have more comorbidities than those
in previously published reports on patients treated with
conventional bioprosthetic valves.
Study limitations. The incidence of CeV in prior studies
aries depending on how these events were diagnosed (24).
n this study, neurologists and internists diagnosed these
vents clinically and, therefore, an underestimation of events
ay be possible. Similarly, transapical patients in a surgical
ntensive care unit setting may be less likely to have stroke
iagnosed than transarterial patients on a medical ward
ould. The use of Rankin scores or National Institutes of
ealth scores would have allowed more objective assess-
ent of such events. This study focused predominantly on
vert, clinical CeV, as most of these events occurred before
he change in the guidelines. Recent studies comparing
agnetic resonance imaging before and after TAVI show a
uch higher incidence of subclinical stroke (25,26). It is
uncertain if patients who experience subclinical strokes have
a similar prognosis to those who have overt symptoms.
Therefore, it is imperative that future studies are done by
standardizing the definitions of CeV (e.g., using the Valve
Academic Research Consortium definitions [27]), the type
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1296and modality of neuroimaging, and the timing of evaluation
to allow a more precise estimate of risks. In this study, we
were also unable to explore the relationship between indi-
vidual components of the cerebrovascular disease (carotid
stenosis, endarterectomy, and previous TIA or strokes) on
the risk of further events, as the number of patients who had
baseline carotid imaging was few and this was not
standardized.
The exclusion of PARTNER patients was necessary, as
this trial was ongoing at the time of the study. In addition,
this study was also performed to understand the clinical
characteristics and outcomes of patients who did not fulfill
the inclusion/exclusion criteria to the PARTNER trial.
However, the numbers of patients excluded was small (n 
19), and they did not affect the results when they were
included in the analysis.
The small number of patients and heterogeneous use of
antiplatelet agents and VKA alone or in combination does
not allow determination of which strategy is more effective.
Among those who received antithrombotic therapies, we
were unable to determine if all patients were at therapeutic
levels.
With a more standardized antiplatelet/antithrombotic
protocol in future, a more meaningful comparison can be
made with regards their effect on preventing CeV.
Although we have noted a relationship of CeV with a
prior history of cerebrovascular disease, the small number of
patients in this study leads to it being underpowered and a
beta error cannot be ruled out with certainty. Also, the
ability of multivariable methods to identify independent
predictors with only 23 CvE is very limited. However, the
clinical relationship remains highly plausible.
Conclusions
The incidence of CeV appears highest in the first 24 h after
TAVI, but, importantly, it also remains elevated for 2
months. Patients with a prior history of cerebrovascular
disease are at higher risk. This may have implications for
patient selection and antithrombotic strategies.
Reprint requests and correspondence: Dr. John G. Webb, St.
Paul’s Hospital, 1081 Burrard Street, Vancouver, British Colum-
bia V6Z 1Y6, Canada. E-mail: webb@providencehealth.ca.
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